CD19/20 Bispecific Nanobody-derived CAR-T Cells in B Cell Lymphoma

Status Recruiting

Clinical Trial Summary

Evaluation the safety and efficacy of CD19/CD20 bispecific CAR-T cells in patients with relapsed/refractory B cell lymphoma

Clinical Trial Description

CART cell therapy has become the treatment of choice for patients with relapsed/ refractory B cell lymphoma. Currently, CAR-T cells approved for relapsed/refractory B-cell lymphoma are mainly CAR19-T cells. Nearly half of patients who relapse after treatment with CAR19-T cells are caused by tumor cell antigen escape. Dual-target CAR-T cells targeting CD19 and CD20 may reduce the recurrence rate after treatment. This study was to evaluate the efficacy and safety of CD19/CD20 bispecific CAR-T cells in patients with relapsed/refractory B cell lymphoma. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03881761
Study type	Interventional
Source	Henan Cancer Hospital
Contact	Yongping Song, Dr.
Phone	+86-37165587795
Email	songyongping2018@126.com
Status	Recruiting
Phase	Phase 1
Start date	February 1, 2019
Completion date	January 31, 2022

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT06038422` - GTP Regimen in the Treatment of Refractory/Recurrent HLH	Phase 3
Not yet recruiting	`NCT06090864` - ATLCAR.CD30.CCR4 for CD30+ HL ATLCAR.CD30.CCR4 Cells	Phase 1/Phase 2
Active, not recruiting	`NCT02280993` - Phase I/II Feasibility Study Combining Brentuximab Vedotin With Second Line Salvage Chemotherapy (DHAP) in Hodgkin Lymphoma Patients	Phase 1
Completed	`NCT00752518` - A Japan Phase I/II Study of Bortezomib in Relapsed or Refractory Multiple Myeloma Patients	Phase 1/Phase 2
Active, not recruiting	`NCT03085173` - A Trial of "Armored" CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies	Phase 1
Active, not recruiting	`NCT03179930` - Combination Therapy With Entinostat and Pembrolizumab in Relapsed and Refractory Lymphomas	Phase 2
Recruiting	`NCT03275493` - Humanized CD19 CAR-T Cells With CRS Suppression Technology for r/r CD19+ Acute Lymphoblastic Leukemia	Phase 1/Phase 2
Recruiting	`NCT05153330` - Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL	Phase 1
Recruiting	`NCT03881774` - Cord Blood Derived CAR-T Cells in Refractory/Relapsed B Cell Malignancies	Phase 1
Recruiting	`NCT02407275` - Rhinosinusites Chroniques	N/A
Recruiting	`NCT05911321` - Isa-Pom-Dex in Elderly/Frail Subjects With RRMM	Phase 2
Not yet recruiting	`NCT04599452` - NK Cell Therapy Recurrent/Refractory Elderly AML	Phase 1/Phase 2
Not yet recruiting	`NCT06265545` - Multicenter, Platform-type Clinical Study of Refractory/Recurrent Acute Myeloid Leukemia	N/A